{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266938","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.817167+00:00","generated_at":"2026-05-17T00:10:48.753096+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight Q3 revenue down 14% YoY to $30.3M; net loss widens to $9.8M","bullets":["Revenue $30.3M (-14% YoY); LAL volume up 6% but LDD placements down 68%.","Net loss $(9.8)M ($(0.24)/share) vs $(6.3)M ($(0.16)/share) in Q3 2024.","Adjusted net loss $(1.7)M ($(0.04)/share) vs adjusted net gain $0.2M prior year.","Narrowed FY2025 revenue guidance to $125-130M (prior $120-130M); raised gross margin guidance to 76-77%.","Cash and investments $227.5M, unchanged from June 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266938","json":"https://secwatch.observer/filing/0001193125-25-266938.json","markdown":"https://secwatch.observer/filing/0001193125-25-266938.md","text":"https://secwatch.observer/filing/0001193125-25-266938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000119312525266938/0001193125-25-266938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000119312525266938/rxst-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:10:48.753096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}